User got a hair transplant and it improved their life. Transplanted hair lasts, but medication like finasteride is needed to maintain non-transplanted hair.
The user has been using RU58841 for about 2 months without noticeable results or side effects and is unsure if this duration is sufficient to judge its effectiveness. Other users suggest continuing the treatment for at least 6 months and ensuring the product's authenticity.
User experienced scarring from microneedling at fast speed and paused treatment for 3-4 weeks to recover. Advice given includes waiting a full month for recovery to avoid scars.
The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.
The user reports that after 4 months of microneedling, 10 months of Minoxidil, 2 years of finasteride, and using ketoconazole 3 times a week, their hair has become less dense in the treated areas. Despite initial shedding and continued treatment, they have not seen improvement and feel their body is resistant to the medications.
The user lost hair progress while in jail due to stopping treatments like oral dutasteride, topical applications, and ketoconazole shampoo. They plan to restart their regimen and hope to recover in about 18 months.
Cold shock therapy may promote hair growth by stimulating follicular muscles and affecting stem cells. The exact mechanisms and full range of elements involved are not yet fully understood.
A user's experience with Pyrilutamide, which they have been taking for 3 months to treat their aggressive male pattern baldness. The user reported that the medication decreased shedding and was hopeful it would work as advertised.
A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.
A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
A user shared their 11-year journey with alopecia, using finasteride, dutasteride, and a hair transplant. They encouraged others not to panic, noting that hair miniaturization can take over 15 years to complete.
COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.
A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
A user shared their 4-month hair transplant progress with 3740 grafts, showing before and after pictures. They had a generally good experience, except for the anesthesia part.
The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.
The user started using topical minoxidil, oral finasteride, GHK-CU, and HGH in October, resulting in thicker hair and improved overall health. They experienced minor side effects like dehydration from HGH but reported benefits like clearer skin, better recovery, and muscle gain.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.
Microneedling's long-term effects on hair loss are uncertain, with concerns about scarring and the need for continued use of minoxidil and finasteride to maintain gains. Finasteride does not sustain minoxidil-regrown hair without ongoing minoxidil use, and microneedling alone shows limited evidence of effectiveness.
A user experienced hair regrowth after 6 months on finasteride, which is earlier than the usual 12-18 months observed by their dermatologist. The dermatologist noted this as an exceptionally good response.
Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.
After using finasteride for 7 months and dutasteride for 5 months, the user experienced a significant reduction in hair shedding and scalp itchiness. They advise patience with hair loss treatments and suggest focusing on a good haircut and reducing stress.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.